| EMA number | EMEA/H/C/000674 |
| ATC code | J07BK02 |
| Authorisation | 19 May 2006 |
| Withdrawn | 1 June 2025 |
| Revision | 33 |
Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. Zostavax is indicated for immunisation of individuals 50 years of age or older.